This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

George E. Ehrlich, MD

JAMA. 1982;248(14):1743-1744.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Severe progressive rheumatoid arthritis remains a therapeutic challenge. The usual approach has been described by Wilbur Blechman as resembling choices from a Cantonese restaurant menu—take one or more from column A and also from column B. Thus, the control of inflammation, or at least of the symptoms produced by inflammation, is made a responsibility of nonsteroidal antiinflammatory drugs and, in some cases, of corticosteroids. At the same time, inhibition of the progression of the disease generally requires addition of disease-modifying antirheumatic drugs, also known as remission-inducing drugs, such as gold salts, penicillamine, antimalarials, azathioprine, and a variety of experimental drugs and procedures borrowed from the treatment of other diseases. Gold compounds were first introduced because of a confusion between tuberculosis and rheumatoid arthritis; penicillamine began as an agent to remove copper from patients who had Wilson's disease; chloroquine and hydroxychloroquine sulfate were used to prevent or treat malaria, while azathioprine . . . [Full Text PDF of this Article]

Author Affiliations
Hahnemann Medical College and Hospital Philadelphia

Footnotes
Address editorial communications to the Editor, 535 N Dearborn St, Chicago, IL 60610.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?